Product Description
DA-8031 is a potent and selective serotonin transporter inhibitor developed for the treatment of premature ejaculation. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23968141/)
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location: Asia Pacific
Company Founding Year: 1932
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Premature Ejaculation|Obstetric Labor, Premature
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01104948 |
DA-8031 | P1 |
Completed |
Healthy Volunteers |
2011-10-01 |
2019-03-19 |
||
NCT01798667 |
DA8031_PE_II | P2 |
Unknown status |
Premature Ejaculation|Obstetric Labor, Premature |
2013-04-01 |
2019-03-19 |
Treatments |